Fierce Biotech August 22, 2024
While the biotech investment scene in Europe has slowed somewhat following a COVID-19 funding boom in 2021, a new report from PitchBook suggests venture capital firms looking at opportunities across the pond could soon have more cash to spare.
PitchBook’s report—which focuses on valuations in Europe broadly and not just in the life sciences sphere—highlights three main “pillars” that the data outfit believes are dominating the VC landscape in Europe in 2024: rates, recovery and rationalization.
Trends in rates and recovery seem to be heading north, the report suggests, citing the European Central Bank and the Bank of England’s recent moves to cut rates at the beginning of the month.
With that in mind, the degree to which valuations have...
Today's Sponsors
Today's Sponsor